We previously demonstrated a unique protective role for the @entity13270 ( @entity13270 ) cation channel in @entity0 cells. In the present study, we investigated the chemotherapeutic effects elicited by inhibiting this protective role in metastatic @entity0 cells. @entity13270 inhibition led to dose-dependent increases in MDA-MB-231 @entity0 cell death after treatment with @entity632 or the DNA-methylating agent, @entity2482 . Similar results were observed after RNAi silencing of @entity13270 in these cells after @entity632 treatment. However, @entity13270 RNAi silencing also led to increased MCF-7 @entity0 cell death after @entity440 treatment, yet not in non-cancerous @entity1 mammary epithelial cells. These results thus revealed that @entity13270 inhibition selectively increased @entity137 in a triple-negative and an @entity172 receptor-positive @entity0 cell line, with minimal deleterious effects in non-cancerous breast cells. Analysis of DNA damage revealed enhanced DNA damage levels in MCF-7 cells treated with @entity632 due to @entity13270 inhibition. Analysis of cell death demonstrated that inhibition of apoptosis, caspase-independent cell death or autophagy failed to significantly reduce cell death induced by @entity13270 inhibition and chemotherapy. These results indicate that @entity13270 inhibition activates alternative pathways of cell death in @entity0 cells. Taken together, our results provide significant evidence that @entity13270 inhibition is a potential strategy to induce triple-negative and @entity172 receptor-positive @entity0 cell death via alternative cell death pathways. This is expected to provide a basis for inhibiting @entity13270 for the improved treatment of @entity0 , which potentially includes treating @entity0 that are resistant to chemotherapy due to their evasion of apoptosis.

Enhanced XXXX in triple-negative and @entity172 receptor  -positive @entity0 cells due to inhibition of the transient receptor potential melastatin-2 channel.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['human'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity13270 :: ('7226', 'Gene') :: ['TRPM2', 'transient receptor potential, melastatin-2'] @entity2482 :: ('MESH:D008769', 'Chemical') :: ["N-methyl-N'-nitro-N-nitrosoguanidine"] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast tumors', 'breast adenocarcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']
@entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']
